In its largest single-asset purchase ever, Takeda snaps up TYK2 drug [from SV portfolio company, Nimbus] for $4B upfront

in Portfolio News

Takeda is buying Nimbus’ late-stage TYK2 inhibitor, an oral drug for autoimmune diseases, for $4 billion in cash upfront. That sets Takeda up to compete with Bristol Myers Squibb, which got the first TYK2 inhibitor approval in September for psoriasis.

View the article
Investing in Women Code Logo

We invest in talented innovators. We strongly adhere to the view that diversity, including under-represented groups, strongly adds to success. If you are an entrepreneur seeking investment and a partner who can help you to build your business, we would love to hear from you. Please get in contact with our team.